Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

Apoptotic and anti-angiogenic effects of Salvia triloba extract in prostate cancer cell lines

Authors: Harika Atmaca, Emir Bozkurt

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Plants, due to their remarkable composition, are considered as natural resources of bioactive compounds with specific biological activities. Salvia genus (Lamiaceae) has been used around the world in complementary medicine since ancient times. We investigated the cytotoxic, apoptotic and anti-angiogenic effects of methanolic Salvia triloba extract (STE) in prostate cancer cells. Cell viability was evaluated by XTT; apoptosis was investigated by DNA fragmentation and caspase 3/7 activity assays. Changes in the angiogenic cytokine levels were investigated by human angiogenesis antibody array. Scratch assay was used to determine the cell motility. STE induced cytotoxicity and apoptosis in a concentration-dependent manner in both cancer cells; however, it was not cytotoxic to normal cells. Cell motility was reduced in PC-3, DU-145 and HUVEC cells by STE treatment. ANG, ENA-78, bFGF, EGF, IGF-1 and VEGF-D levels were significantly decreased by −2.9, −3.7, −1.7, −1.7, −2.0 and −1.8 fold in STE-treated DU-145 cells, however, ANG, IL-8, LEP, RANTES, TIMP-1, TIMP-2 and VEGF levels were significantly decreased by −5.1, −2.0, −2.4, −3.1, −1.5, −2.0 and −2.5 fold in PC-3 cells. These data suggest that STE might be a promising candidate for anti-tumor and anti-angiogenic treatment of prostate cancer.
Literature
1.
Chan HH, Hwang TL, Su CR, Reddy MV, Wu TS. Anti-inflammatory, anticholinesterase and antioxidative constituents from the roots and the leaves of Salvianipponica Miq. var. Formosan. Phytomedicine. 2011;15:148–50.CrossRef
2.
Fiore G, Nencini C, Cavallo F, Capasso A, Bader A, Giorgi G, et al. In vitro antiproliferative effect of six Salvia species on human tumor cell lines. Phytother Res. 2006;20:701–3.CrossRefPubMed
3.
Gong Y, Li Y, Lu Y, Li L, Abdolmaleky H, Blackburn GL, et al. Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int J Cancer. 2011;1:1042–52.CrossRef
4.
Hayat MA. (2011). Tumors of the central nervous system, Vol 12. USA.
5.
Tiwari M. Apoptosis: Angiogenesis and Cancer Therapies. J Cancer Ther Res. 2012;1:1–3.CrossRef
6.
Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, et al. Profiling of angiogenic cytokines produced by hormone- and drug –refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. Eur Cytokine Netw. 2008;1:176–84.
7.
Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed
8.
Keshavarz M, Mostafaie A, Mansouri K, Bidmeshkipour A, Motlagh HR, Parvaneh S. In vitro and ex vivo antiangiogenic activity of Salvia officinalis. Phytother Res. 2010;24:1526–31.CrossRefPubMed
9.
Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7:115–22.CrossRefPubMed
10.
Horiuchi K, Shiota S, Hatano T, Yoshida T, Kuroda T, Tsuchiy T. Antimicrobial activity of oleanolic acid from Salvia officinalis and related compounds on vancomycin resistant enterococci (VRE). Biol Pharm Bull. 2007;30:1147–9.CrossRefPubMed
11.
Shakiba Y, Mansouri K, Mostafaie A. Anti-angiogenic effect of soybean kunitz trypsin inhibitor on human umbilical vein endothelial cells. Fitoterapia. 2007;78:587–9.CrossRefPubMed
12.
Bors W, Michel C, Stettmaier K, Lu Y, Foo LY. Antioxidant mechanisms of polyphenolic caffeic acid oligomers, constituents of Salvia officinalis. Biol Res. 2004;37:301–11.CrossRefPubMed
13.
Moretti MDL, Peana AT, Sata M. A study on anti-inflammatory and peripheral analgesic action of Salvia sclarea oil and its main components. JEOR. 1997;9:199–204.CrossRef
14.
Skjøth IH, Issinger OG. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol. 2006;28:217–29.PubMed
15.
Papageorgiou V, Gardeli C, Mallouchos A, Papaioannou M, Komaitis M. Variation of the Chemical Profile and Antioxidant Behavior of Rosmarinus officinalis L. and Salvia fruticosa Miller Grown in Greece. J Agric Food Chem. 2008;56:7254–64.CrossRefPubMed
16.
Al-Kalaldeh JZ, Abu-Dahab R, Afifi FU. Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells. Nutr Res. 2010;30:271–8.CrossRefPubMed
17.
Kaileh M, Vanden Berghe W, Boone E, Essawi T, Haegeman G. Screening of indigenous Palestinian medicinal plants for potential anti-inflammatory and cytotoxic activity. J Ethnopharmacol. 2007;25:510–6.CrossRef
18.
Xavier CP, Lima CF, Fernandes-Ferreira M, Pereira-Wilson C. Salvia fruticosa, Salvia officinalis, and rosmarinic acid induce apoptosis and inhibit proliferation of human colorectal cell lines: the role in MAPK/ERK pathway. Nutr Cancer. 2009;61:564–71.CrossRefPubMed
19.
20.
Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007;117:2766–77.CrossRefPubMedPubMedCentral
21.
22.
George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Cancer and Leukemia Group B 9480. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia group B 9480. Clin Cancer Res. 2001;7:1932–6.PubMed
Metadata
Title
Apoptotic and anti-angiogenic effects of Salvia triloba extract in prostate cancer cell lines
Authors
Harika Atmaca
Emir Bozkurt
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4208-2

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer

Original Article

CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma

Review

Lin28: an emerging important oncogene connecting several aspects of cancer

Original Article

Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma

Original Article

Deregulation of miR-93 and miR-143 in human esophageal cancer

Original Article

Increased expression of C-C motif ligand 2 associates with poor prognosis in patients with gastric cancer after gastrectomy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits